Targeting voltage-gated calcium channels in neurological and psychiatric diseases

Nature Reviews Drug Discovery

Volumn 15, Issue 1, 2016, Pages 19-34

  Zamponi, Gerald W ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 639; CALCIUM CHANNEL BLOCKING AGENT; CILNIDIPINE; CNV 2197944; ETHOSUXIMIDE; GABAPENTIN; ISRADIPINE; LAMOTRIGINE; NIFEDIPINE; NIMODIPINE; NMED 126; NP 078585; OMEGA CONOTOXIN MVIIA; PREGABALIN; PRENYLAMINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VERAPAMIL; VOLTAGE GATED CALCIUM CHANNEL; Z 160; Z 944; ZONISAMIDE; CALCIUM CHANNEL;

BIPOLAR DISORDER; BLOOD BRAIN BARRIER; BRAIN FUNCTION; DRUG DEPENDENCE; DRUG TARGETING; EPILEPSY; HUMAN; MENTAL DISEASE; NEURALGIA; NEUROLOGIC DISEASE; NEUROPATHY; NONHUMAN; PAIN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SYNAPSE; ANIMAL; BIOLOGICAL MODEL; MENTAL DISORDERS; METABOLISM; MOLECULARLY TARGETED THERAPY; NERVOUS SYSTEM DISEASES; PROCEDURES;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; HUMANS; MENTAL DISORDERS; MODELS, NEUROLOGICAL; MOLECULAR TARGETED THERAPY; NERVOUS SYSTEM DISEASES;

EID: 84955186743     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2015.5     Document Type: Review

References (243)

1. Cain, S. M. & Snutch, T. P. T type calcium channels in burst-firing, network synchrony, and epilepsy. Biochim. Biophys. Acta 1828, 1572-1578 (2013).
2. Hook, S. S. & Means, A. R. Ca2+/CaM-dependent kinases: from activation to function. Annu. Rev. Pharmacol. Toxicol. 41, 471-505 (2001).
3. Wheeler, D. B., Randall, A. & Tsien, R. W. Roles of N type and Q type Ca2+ channels in supporting hippocampal synaptic transmission. Science 264, 107-111 (1994).
4. Dolmetsch, R. E., Pajvani, U., Fife, K., Spotts, J. M. & Greenberg, M. E. Signaling to the nucleus by an L type calcium channel-calmodulin complex through the MAP kinase pathway. Science 294, 333-339 (2001).
5. Wheeler, D. G. et al. CaV1 and CaV2 channels engage distinct modes of Ca2+ signaling to control CREB-dependent gene expression. Cell 149, 1112-1124 (2012).
6. Tanabe, T., Beam, K. G., Adams, B. A., Niidome, T. & Numa, S. Regions of the skeletal muscle dihydropyridine receptor critical for excitation-contraction coupling. Nature 346, 567-569 (1990).
7. Simms, B. A. & Zamponi, G. W. Neuronal voltage-gated calcium channels: structure, function, and dysfunction. Neuron 82, 24-45 (2014).
8. Catterall, W. A., Perez-Reyes, E., Snutch, T. P. & Striessnig, J. International union of pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol. Rev. 57, 411-425 (2005).
9. Lipscombe, D., Andrade, A. & Allen, S. E. Alternative splicing: functional diversity among voltage-gated calcium channels and behavioral consequences. Biochim. Biophys. Acta 1828, 1522-1529 (2013).
10. Dolphin, A. C. Calcium channel auxiliary α2δ and β subunits: trafficking and one step beyond. Nat. Rev. Neurosci. 13, 542-555 (2012).
11. Lory, P. & Mezghrani, A. Calcium channelopathies in inherited neurological disorders: relevance to drug screening for acquired channel disorders. IDrugs 13, 467-471 (2010).
12. Felix, R. Calcium channelopathies. Neuromolecular Med. 8, 307-318 (2006).
13. Bean, B. P. Classes of calcium channels in vertebrate cells. Annu. Rev. Physiol. 51, 367-384 (1989).
14. Nowycky, M. C., Fox, A. P. & Tsien, R. W. Three types of neuronal calcium channel with different calcium agonist sensitivity. Nature 316, 440-443 (1985).
15. Perez-Reyes, E. Molecular physiology of low-voltage-activated t type calcium channels. Physiol. Rev. 83, 117-161 (2003).
16. Bourinet, E. et al. Splicing of α1A subunit gene generates phenotypic variants of P- and Q type calcium channels. Nat. Neurosci. 2, 407-415 (1999).
17. Richards, K. S., Swensen, A. M., Lipscombe, D. & Bommert, K. Novel CaV2. 1 clone replicates many properties of Purkinje cell CaV2. 1 current. Eur. J. Neurosci. 26, 2950-2961 (2007).
18. Catterall, W. A. Ion channel voltage sensors: structure, function, and pathophysiology. Neuron 67, 915-928 (2010).
19. Bladen, C. & Zamponi, G. W. Common mechanisms of drug interactions with sodium and T type calcium channels. Mol. Pharmacol. 82, 481-487 (2012).
20. Sinnegger, M. J. et al. Nine L type amino acid residues confer full 1, 4 dihydropyridine sensitivity to the neuronal calcium channel α1A subunit. Role of L type Met1188. J. Biol. Chem. 272, 27686-27693 (1997).
21. Striessnig, J. et al. Structural basis of drug binding to L Ca2+ channels. Trends Pharmacol. Sci. 19, 108-115 (1998).
22. Catterall, W. A. Voltage-gated calcium channels. Cold Spring Harb. Perspect. Biol. 3, a003947 (2011).
23. Pragnell, M. et al. Calcium channel β-subunit binds to a conserved motif in the I-II cytoplasmic linker of the α1 subunit. Nature 368, 67-70 (1994).
24. Dolphin, A. C. The α2δ subunits of voltage-gated calcium channels. Biochim. Biophys. Acta 1828, 1541-1549 (2012).
25. Altier, C. et al. The Cavsubunit prevents RFP2 mediated ubiquitination and proteasomal degradation of L type channels. Nat. Neurosci. 14, 173-180 (2011). This paper shows that ancillary Cav subunits regulate calcium channel trafficking by interfering with the ubiquitylation of the channels.
26. Tran-Van-Minh, A. & Dolphin, A. C. The α2δ ligand gabapentin inhibits the Rab11 dependent recycling of the calcium channel subunit α2δ 2. J. Neurosci. 30, 12856-12867 (2010).
27. Kang, M. G. & Campbell, K. P. Gamma subunit of voltage-activated calcium channels. J. Biol. Chem. 278, 21315-21318 (2003).
28. Lipscombe, D., Andrade, A. & Allen, S. E. Alternative splicing: functional diversity among voltage-gated calcium channels and behavioral consequences. Biochim. Biophys. Acta 1828, 1522-1529 (2012).
29. Sinnegger-Brauns, M. J. et al. Expression and 1, 4 dihydropyridine-binding properties of brain L type calcium channel isoforms. Mol. Pharmacol. 75, 407-414 (2009).
30. Hell, J. W. et al. Identification and differential subcellular localization of the neuronal class C and class D L type calcium channel α1 subunits. J. Cell Biol. 123, 949-962 (1993).
31. Hutchinson, T. E., Zhong, W., Chebolu, S., Wilson, S. M. & Darmani, N. A. L type calcium channels contribute to 5 HT3 receptor-evoked CaMKIIα and ERK activation and induction of emesis in the least shrew (Cryptotis parva). Eur. J. Pharmacol. 755, 110-118 (2015).
32. Ramirez-Latorre, J. A. Functional upregulation of Ca2+-activated K+ channels in the development of substantia nigra dopamine neurons. PLoS ONE 7, e51610 (2012).
33. Brandt, A., Khimich, D. & Moser, T. Few CaV1. 3 channels regulate the exocytosis of a synaptic vesicle at the hair cell ribbon synapse. J. Neurosci. 25, 11577-11585 (2005).
34. Platzer, J. et al. Congenital deafness and sinoatrial node dysfunction in mice lacking class D L type Ca2+ channels. Cell 102, 89-97 (2000).
35. Baig, S. M. et al. Loss of CaV1. 3 (CACNA1D) function in a human channelopathy with bradycardia and congenital deafness. Nat. Neurosci. 14, 77-84 (2011).
36. Lodha, N. et al. Congenital stationary night blindness in mice-a tale of two Cacna1f mutants. Adv. Exp. Med. Biol. 664, 549-558 (2010).
37. Lodha, N., Loucks, C. M., Beaulieu, C., Parboosingh, J. S. & Bech-Hansen, N. T. Congenital stationary night blindness: mutation update and clinical variability. Adv. Exp. Med. Biol. 723, 371-379 (2012).
38. Zamponi, G. W. Regulation of presynaptic calcium channels by synaptic proteins. J. Pharmacol. Sci. 92, 79-83 (2003).
39. Cao, Y. Q. et al. Presynaptic Ca2+ channels compete for channel type-preferring slots in altered neurotransmission arising from Ca2+ channelopathy. Neuron 43, 387-400 (2004).
40. Hatakeyama, S. et al. Differential nociceptive responses in mice lacking the α1B subunit of N type Ca2+ channels. Neuroreport 12, 2423-2427 (2001).
41. Jun, K. et al. Ablation of P/Q type Ca2+ channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the alpha1A-subunit. Proc. Natl Acad. Sci. USA 96, 15245-15250 (1999).
42. Sutton, K. G., McRory, J. E., Guthrie, H., Murphy, T. H. & Snutch, T. P. P/Q type calcium channels mediate the activity-dependent feedback of syntaxin 1A. Nature 401, 800-804 (1999).
43. Vecchia, D., Tottene, A., van den Maagdenberg, A. M. & Pietrobon, D. Abnormal cortical synaptic transmission in CaV2. 1 knockin mice with the S218L missense mutation which causes a severe familial hemiplegic migraine syndrome in humans. Front. Cell Neurosci. 9, 8 (2015).
44. Nachbauer, W. et al. Episodic ataxia type 2: phenotype characteristics of a novel CACNA1A mutation and review of the literature. J. Neurol. 261, 983-991 (2014).
45. Saegusa, H. et al. Properties of human Cav2. 1 channel with a spinocerebellar ataxia type 6 mutation expressed in Purkinje cells. Mol. Cell Neurosci. 34, 261-270 (2007).
46. Groen, J. L. et al. CACNA1B mutation is linked to unique myoclonus-dystonia syndrome. Hum. Mol. Genet. 24, 987-993 (2015).
47. Wu, L. G., Borst, J. G. & Sakmann, B. R type Ca2+ currents evoke transmitter release at a rat central synapse. Proc. Natl Acad. Sci. USA 95, 4720-4725 (1998).
48. Ricoy, U. M. & Frerking, M. E. Distinct roles for Cav2. 1-2. 3 in activity-dependent synaptic dynamics. J. Neurophysiol. 111, 2404-2413 (2014).
49. Zaman, T. et al. Cav2. 3 channels are critical for oscillatory burst discharges in the reticular thalamus and absence epilepsy. Neuron 70, 95-108 (2011).
50. Coulter, D. A., Huguenard, J. R. & Prince, D. A. Calcium currents in rat thalamocortical relay neurones: kinetic properties of the transient, low-threshold current. J. Physiol. 414, 587-604 (1989).
51. Molineux, M. L. et al. Specific T type calcium channel isoforms are associated with distinct burst phenotypes in deep cerebellar nuclear neurons. Proc. Natl Acad. Sci. USA 103, 5555-5560 (2006).
52. Chemin, J., Monteil, A., Bourinet, E., Nargeot, J. & Lory, P. Alternatively spliced α1G (Cav3. 1) intracellular loops promote specific T type Ca2+ channel gating properties. Biophys. J. 80, 1238-1250 (2001).
53. Weiss, N. et al. A Cav3. 2/syntaxin 1A signaling complex controls T type channel activity and low-threshold exocytosis. J. Biol. Chem. 287, 2810-2818 (2012).
54. Fleckenstein, A., Kammermeier, H., Doring, H. J. & Freund, H. J. [On the method of action of new types of coronary dilatators with simultaneous oxygen-saving myocardial effects, prenylamine and iproveratril. 2]. Z. Kreislaufforsch. 56, 839-858 (1967).
55. Doering, C. J. & Zamponi, G. W. Molecular pharmacology of high voltage-activated calcium channels. J. Bioenerg. Biomembr. 35, 491-505 (2003).
56. Glossmann, H., Ferry, D. R., Lubbecke, F., Mewes, R. & Hofmann, F. Identification of voltage operated calcium channels by binding studies: differentiation of subclasses of calcium antagonist drugs with 3H nimodipine radioligand binding. J. Recept. Res. 3, 177-190 (1983).
57. Glossmann, H., Ferry, D. R., Goll, A. & Rombusch, M. Molecular pharmacology of the calcium channel: evidence for subtypes, multiple drug-receptor sites, channel subunits, and the development of a radioiodinated 1, 4 dihydropyridine calcium channel label, [125I]iodipine. J. Cardiovasc. Pharmacol. 6 (Suppl. 4), 608-621 (1984).
58. Benjamin, E. R. et al. Pharmacological characterization of recombinant N type calcium channel (Cav2. 2) mediated calcium mobilization using FLIPR. Biochem. Pharmacol. 72, 770-782 (2006).
59. Xie, X. et al. Validation of high throughput screening assays against three subtypes of Cav3 T type channels using molecular and pharmacologic approaches. Assay Drug Dev. Technol. 5, 191-203 (2007).
60. Vetter, I. Development and optimization of FLIPR high throughput calcium assays for ion channels and GPCRs. Adv. Exp. Med. Biol. 740, 45-82 (2012).
61. Tao, H. et al. Efficient characterization of use-dependent ion channel blockers by real-time monitoring of channel state. Assay Drug Dev. Technol. 4, 57-64 (2006).
62. Dai, G. et al. A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors. Assay Drug Dev. Technol. 6, 195-212 (2008).
63. Belardetti, F. et al. A fluorescence-based high-throughput screening assay for the identification of T type calcium channel blockers. Assay Drug Dev. Technol. 7, 266-280 (2009).
64. Balasubramanian, B. et al. Optimization of Cav1. 2 screening with an automated planar patch clamp platform. J. Pharmacol. Toxicol. Methods 59, 62-72 (2009).
65. Kraus, R. et al. Identification of benz(othi)azepine-binding regions within L type calcium channel α1 subunits. J. Biol. Chem. 271, 20113-20118 (1996).
66. Stotz, S. C., Jarvis, S. E. & Zamponi, G. W. Functional roles of cytoplasmic loops and pore lining transmembrane helices in the voltage-dependent inactivation of HVA calcium channels. J. Physiol. 554, 263-273 (2004).
67. Zamponi, G. W. et al. Unique structure-activity relationship for 4 isoxazolyl 1, 4 dihydropyridines. J. Med. Chem. 46, 87-96 (2003).
68. Catterall, W. A. & Swanson, T. M. Structural basis for pharmacology of voltage-gated sodium and calcium channels. Mol. Pharmacol. 88, 141-150 (2015).
69. Bladen, C., Gunduz, M. G., Simsek, R., Safak, C. & Zamponi, G. W. Synthesis and evaluation of 1, 4 dihydropyridine derivatives with calcium channel blocking activity. Pflugers Arch. 466, 1355-1363 (2014).
70. Fujii, S., Kameyama, K., Hosono, M., Hayashi, Y. & Kitamura, K. Effect of cilnidipine, a novel dihydropyridine Ca++-channel antagonist, on N type Ca++ channel in rat dorsal root ganglion neurons. J. Pharmacol. Exp. Ther. 280, 1184-1191 (1997).
71. Kumar, P. P. et al. Synthesis and evaluation of a new class of nifedipine analogs with T type calcium channel blocking activity. Mol. Pharmacol. 61, 649-658 (2002).
72. Basbaum, A. I., Bautista, D. M., Scherrer, G. & Julius, D. Cellular and molecular mechanisms of pain. Cell 139, 267-284 (2009).
73. Bourinet, E. et al. Calcium-permeable ion channels in pain signaling. Physiol. Rev. 94, 81-140 (2014).
74. Waxman, S. G. & Zamponi, G. W. Regulating excitability of peripheral afferents: emerging ion channel targets. Nat. Neurosci. 17, 153-163 (2014).
75. Cizkova, D. et al. Localization of N type Ca2+ channels in the rat spinal cord following chronic constrictive nerve injury. Exp. Brain Res. 147, 456-463 (2002).
76. Marger, F. et al. T type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome. Proc. Natl Acad. Sci. USA 108, 11268-11273 (2011).
77. Jagodic, M. M. et al. Upregulation of the T type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J. Neurophysiol. 99, 3151-3156 (2008).
78. Tedford, H. W. & Zamponi, G. W. Direct G protein modulation of Cav2 calcium channels. Pharmacol. Rev. 58, 837-862 (2006).
79. Jiang, Y. Q., Andrade, A. & Lipscombe, D. Spinal morphine but not ziconotide or gabapentin analgesia is affected by alternative splicing of voltage-gated calcium channel Cav2. 2 pre-mRNA. Mol. Pain 9, 67 (2013).
80. Kuo, A., Wyse, B. D., Meutermans, W. & Smith, M. T. In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile. Br. J. Pharmacol. 172, 532-548 (2015).
81. Luo, Z. D. et al. Upregulation of dorsal root ganglion α2δ calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J. Neurosci. 21, 1868-1875 (2001).
82. Bauer, C. S. et al. The increased trafficking of the calcium channel subunit α2δ 1 to presynaptic terminals in neuropathic pain is inhibited by the α2δ ligand pregabalin. J. Neurosci. 29, 4076-4088 (2009).
83. Bauer, C. S. et al. The anti-allodynic α2δ ligand pregabalin inhibits the trafficking of the calcium channel α2δ 1 subunit to presynaptic terminals in vivo. Biochem. Soc. Trans. 38, 525-528 (2010).
84. Hendrich, J., Bauer, C. S. & Dolphin, A. C. Chronic pregabalin inhibits synaptic transmission between rat dorsal root ganglion and dorsal horn neurons in culture. Channels 6, 124-132 (2012).
85. Johnson, R. W. & Rice, A. S. Clinical practice. Postherpetic neuralgia. N. Engl. J. Med. 371, 1526-1533 (2014).
86. Miljanich, G. P. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr. Med. Chem. 11, 3029-3040 (2004).
87. Rauck, R. L., Wallace, M. S., Burton, A. W., Kapural, L. & North, J. M. Intrathecal ziconotide for neuropathic pain: a review. Pain Pract. 9, 327-337 (2009).
88. Staats, P. S. et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 291, 63-70 (2004).
89. Smith, H. S. & Deer, T. R. Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain. Ther. Clin. Risk Manag 5, 521-534 (2009).
90. Rauck, R. L. et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J. Pain Symptom Manage. 31, 393-406 (2006).
91. Wallace, M. S. et al. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 9, 75-86 (2006).
92. Feng, Z. P. et al. Determinants of inhibition of transiently expressed voltage-gated calcium channels by w-conotoxins GVIA and MVIIA. J. Biol. Chem. 278, 20171-20178 (2003).
93. Zamponi, G. W. et al. Scaffold-based design and synthesis of potent N type calcium channel blockers. Bioorg. Med. Chem. Lett. 19, 6467-6472 (2009).
94. Swensen, A. M. et al. Characterization of the substituted N triazole oxindole TROX 1, a small-molecule, state-dependent inhibitor of CaV2 calcium channels. Mol. Pharmacol. 81, 488-497 (2012).
95. Ryder, T. R. et al. Multiple parallel synthesis of N, N dialkyldipeptidylamines as N type calcium channel blockers. Bioorg. Med. Chem. Lett. 9, 1813-1818 (1999).
96. Subasinghe, N. L. et al. A novel series of pyrazolylpiperidine N type calcium channel blockers. Bioorg. Med. Chem. Lett. 22, 4080-4083 (2012).
97. Shao, P. P. et al. Aminopiperidine sulfonamide Cav2. 2 channel inhibitors for the treatment of chronic pain. J. Med. Chem. 55, 9847-9855 (2012).
98. Hu, L. Y. et al. Synthesis and biological evaluation of substituted 4-(OBz)phenylalanine derivatives as novel N type calcium channel blockers. Bioorg. Med. Chem. Lett. 9, 1121-1126 (1999).
99. Yamamoto, T. et al. Discovery and evaluation of selective N type calcium channel blockers: 6 unsubstituted- 1, 4 dihydropyridine 5 carboxylic acid derivatives. Bioorg. Med. Chem. Lett. 22, 3639-3642 (2012).
100. Scott, V. E. et al. A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats. Biochem. Pharmacol. 83, 406-418 (2012).
101. Cheng, J. K., Lin, C. S., Chen, C. C., Yang, J. R. & Chiou, L. C. Effects of intrathecal injection of T type calcium channel blockers in the rat formalin test. Behav. Pharmacol. 18, 1-8 (2007).
102. Bourinet, E. et al. Silencing of the Cav3. 2 T type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J. 24, 315-324 (2005).
103. Berger, N. D. et al. NMP 7 inhibits chronic inflammatory and neuropathic pain via block of Cav3. 2 T type calcium channels and activation of CB2 receptors. Mol. Pain 10, 77 (2014).
104. Bladen, C. et al. Characterization of novel cannabinoid based T type calcium channel blockers with analgesic effects. ACS Chem. Neurosci. 6, 277-287 (2015).
105. Gadotti, V. M. et al. Analgesic effect of a mixed T type channel inhibitor/CB2 receptor agonist. Mol. Pain 9, 32 (2013).
106. Bladen, C. et al. 1, 4 dihydropyridine derivatives with T type calcium channel blocking activity attenuate inflammatory and neuropathic pain. Pflugers Arch. 467, 1237-1247 (2014).
107. Lee, M. J. et al. KST5468, a new T type calcium channel antagonist, has an antinociceptive effect on inflammatory and neuropathic pain models. Pharmacol. Biochem. Behav. 97, 198-204 (2010).
108. Choe, W. et al. TTA P2 is a potent and selective blocker of T type calcium channels in rat sensory neurons and a novel antinociceptive agent. Mol. Pharmacol. 80, 900-910 (2011).
109. Chemin, J., Monteil, A., Perez-Reyes, E., Nargeot, J. & Lory, P. Direct inhibition of T type calcium channels by the endogenous cannabinoid anandamide. EMBO J. 20, 7033-7040 (2001).
110. Gilmore, A. J., Heblinski, M., Reynolds, A., Kassiou, M. & Connor, M. Inhibition of human recombinant T type calcium channels by N arachidonoyl 5 HT. Br. J. Pharmacol. 167, 1076-1088 (2012).
111. Hildebrand, M. E. et al. A novel slow-inactivation-specific ion channel modulator attenuates neuropathic pain. Pain 152, 833-843 (2011).
112. Lee, M. Z944: a first in class T type calcium channel modulator for the treatment of pain. J. Peripher Nerv. Syst. 19 (Suppl. 2), 11-12 (2014).
113. Ziegler, D., Duan, W. R., An, G., Thomas, J. W. & Nothaft, W. A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain. Pain 156, 2013-2020 (2015).
114. Terashima, T., Xu, Q., Yamaguchi, S. & Yaksh, T. L. Intrathecal P/Q? and R type calcium channel blockade of spinal substance P release and c Fos expression. Neuropharmacology 75, 1-8 (2013).
115. Matthews, E. A., Bee, L. A., Stephens, G. J. & Dickenson, A. H. The Cav2. 3 calcium channel antagonist SNX 482 reduces dorsal horn neuronal responses in a rat model of chronic neuropathic pain. Eur. J. Neurosci. 25, 3561-3569 (2007).
116. Murakami, M. et al. Antinociceptive effect of different types of calcium channel inhibitors and the distribution of various calcium channel α1 subunits in the dorsal horn of spinal cord in mice. Brain Res. 1024, 122-129 (2004).
117. Saegusa, H. et al. Altered pain responses in mice lacking α1E subunit of the voltage-dependent Ca2+ channel. Proc. Natl Acad. Sci. USA 97, 6132-6137 (2000).
118. Bourinet, E. et al. Interaction of SNX482 with domains III and IV inhibits activation gating of α1E (Cav2. 3) calcium channels. Biophys. J. 81, 79-88 (2001).
119. Ide, S. et al. Association between genetic polymorphisms in Cav2. 3 (R type) Ca2+ channels and fentanyl sensitivity in patients undergoing painful cosmetic surgery. PLoS ONE 8, e70694 (2013).
120. Herman, S. T. Epilepsy after brain insult: targeting epileptogenesis. Neurology 59, S21-S26 (2002).
121. Blumenfeld, H. Cellular and network mechanisms of spike-wave seizures. Epilepsia 46 (Suppl. 9), 21-33 (2005).
122. Noebels, J. L. The biology of epilepsy genes. Annu. Rev. Neurosci. 26, 599-625 (2003).
123. Heron, S. E., Scheffer, I. E., Berkovic, S. F., Dibbens, L. M. & Mulley, J. C. Channelopathies in idiopathic epilepsy. Neurotherapeutics 4, 295-304 (2007).
124. Khosravani, H. & Zamponi, G. W. Voltage-gated calcium channels and idiopathic generalized epilepsies. Physiol. Rev. 86, 941-966 (2006).
125. Luttjohann, A. & van Luijtelaar, G. Dynamics of networks during absence seizures on- and offset in rodents and man. Front. Physiol. 6, 16 (2015).
126. Cheong, E. & Shin, H. S. T type Ca2+ channels in absence epilepsy. Pflugers Arch. 466, 719-734 (2014).
127. Tscherter, A. et al. Minimal alterations in T type calcium channel gating markedly modify physiological firing dynamics. J. Physiol. 589, 1707-1724 (2011).
128. Song, I. et al. Role of the α1G T type calcium channel in spontaneous absence seizures in mutant mice. J. Neurosci. 24, 5249-5257 (2004).
129. Powell, K. L. et al. A Cav3. 2 T type calcium channel point mutation has splice-variant-specific effects on function and segregates with seizure expression in a polygenic rat model of absence epilepsy. J. Neurosci. 29, 371-380 (2009).
130. Zamponi, G. W., Lory, P. & Perez-Reyes, E. Role of voltage-gated calcium channels in epilepsy. Pflugers Arch. 460, 395-403 (2010).
131. Heron, S. E. et al. Extended spectrum of idiopathic generalized epilepsies associated with CACNA1H functional variants. Ann. Neurol. 62, 560-568 (2007).
132. Khosravani, H. et al. Gating effects of mutations in the Cav3. 2 T type calcium channel associated with childhood absence epilepsy. J. Biol. Chem. 279, 9681-9684 (2004).
133. Vitko, I. et al. The I II loop controls plasma membrane expression and gating of Cav3. 2 T type Ca2+ channels: a paradigm for childhood absence epilepsy mutations. J. Neurosci. 27, 322-330 (2007).
134. Eckle, V. S. et al. Mechanisms by which a CACNA1H mutation in epilepsy patients increases seizure susceptibility. J. Physiol. 592, 795-809 (2014).
135. Ernst, W. L., Zhang, Y., Yoo, J. W., Ernst, S. J. & Noebels, J. L. Genetic enhancement of thalamocortical network activity by elevating α1g mediated low-voltage-activated calcium current induces pure absence epilepsy. J. Neurosci. 29, 1615-1625 (2009).
136. Kim, D. et al. Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice lacking α1G T type Ca2+ channels. Neuron 31, 35-45 (2001).
137. Cain, S. M. & Snutch, T. P. Contributions of T type calcium channel isoforms to neuronal firing. Channels 4, 475-482 (2010).
138. Astori, S. et al. The Cav3. 3 calcium channel is the major sleep spindle pacemaker in thalamus. Proc. Natl Acad. Sci. USA 108, 13823-13828 (2011).
139. Lee, S. E. et al. Rebound burst firing in the reticular thalamus is not essential for pharmacological absence seizures in mice. Proc. Natl Acad. Sci. USA 111, 11828-11833 (2014).
140. Huguenard, J. R. Block of T -type Ca2+ channels is an important action of succinimide antiabsence drugs. Epilepsy Curr. 2, 49-52 (2002).
141. Gomora, J. C., Daud, A. N., Weiergraber, M. & Perez-Reyes, E. Block of cloned human T type calcium channels by succinimide antiepileptic drugs. Mol. Pharmacol. 60, 1121-1132 (2001).
142. Todorovic, S. M. & Lingle, C. J. Pharmacological properties of T type Ca2+ current in adult rat sensory neurons: effects of anticonvulsant and anesthetic agents. J. Neurophysiol. 79, 240-252 (1998).
143. Ziyatdinova, S. et al. Spontaneous epileptiform discharges in a mouse model of Alzheimers disease are suppressed by antiepileptic drugs that block sodium channels. Epilepsy Res. 94, 75-85 (2011).
144. Gottlicher, M. et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978 (2001).
145. Matar, N. et al. Zonisamide block of cloned human T type voltage-gated calcium channels. Epilepsy Res. 83, 224-234 (2009).
146. Tanabe, M., Murakami, T. & Ono, H. Zonisamide suppresses pain symptoms of formalin-induced inflammatory and streptozotocin-induced diabetic neuropathy. J. Pharmacol. Sci. 107, 213-220 (2008).
147. Tringham, E. et al. T type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures. Sci. Transl. Med. 4, 121ra19 (2012).
148. Johannessen Landmark, C., Beiske, G., Baftiu, A., Burns, M. L. & Johannessen, S. I. Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. Seizure 28, 88-91 (2015).
149. Iyer, A. & Marson, A. Pharmacotherapy of focal epilepsy. Expert Opin. Pharmacother. 15, 1543-1551 (2014).
150. Glauser, T. A. et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia 54, 141-155 (2013).
151. Hainsworth, A. H., McNaughton, N. C., Pereverzev, A., Schneider, T. & Randall, A. D. Actions of sipatrigine, 202W92 and lamotrigine on R type and T type Ca2+ channel currents. Eur. J. Pharmacol. 467, 77-80 (2003).
152. Dibue, M. et al. Cav 2. 3 (R type) calcium channels are critical for mediating anticonvulsive and neuroprotective properties of lamotrigine in vivo. Epilepsia 54, 1542-1550 (2013).
153. Kuzmiski, J. B., Barr, W., Zamponi, G. W. & MacVicar, B. A. Topiramate inhibits the initiation of plateau potentials in CA1 neurons by depressing R type calcium channels. Epilepsia 46, 481-489 (2005).
154. Radzicki, D. et al. Temperature-sensitive Cav1. 2 calcium channels support intrinsic firing of pyramidal neurons and provide a target for the treatment of febrile seizures. J. Neurosci. 33, 9920-9931 (2013).
155. Furukawa, T. et al. Five different profiles of dihydropyridines in blocking T type Ca2+ channel subtypes (Cav3. 1 (α1G), Cav3. 2 (α1H), and Cav3. 3 (α1I)) expressed in Xenopus oocytes. Eur. J. Pharmacol. 613, 100-107 (2009).
156. Sirven, J. I., Noe, K., Hoerth, M. & Drazkowski, J. Antiepileptic drugs 2012: recent advances and trends. Mayo Clin. Proc. 87, 879-889 (2012).
157. Sulzer, D. & Surmeier, D. J. Neuronal vulnerability, pathogenesis, and Parkinsons disease. Mov. Disord. 28, 715-724 (2013).
158. Zahodne, L. B. & Fernandez, H. H. Pathophysiology and treatment of psychosis in Parkinsons disease: a review. Drugs Aging 25, 665-682 (2008).
159. Connolly, B. S. & Lang, A. E. Pharmacological treatment of Parkinson disease: a review. JAMA 311, 1670-1683 (2014).
160. Kalia, L. V., Kalia, S. K., McLean, P. J., Lozano, A. M. & Lang, A. E. α-synuclein oligomers and clinical implications for Parkinson disease. Ann. Neurol. 73, 155-169 (2013).
161. Nuytemans, K., Theuns, J., Cruts, M. & Van Broeckhoven, C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum. Mutat. 31, 763-780 (2010).
162. Abdel-Salam, O. M. The paths to neurodegeneration in genetic Parkinsons disease. CNS Neurol. Disord. Drug Targets 13, 1485-1512 (2014).
163. Putzier, I., Kullmann, P. H., Horn, J. P. & Levitan, E. S. Cav1. 3 channel voltage dependence, not Ca2+ selectivity, drives pacemaker activity and amplifies bursts in nigral dopamine neurons. J. Neurosci. 29, 15414-15419 (2009).
164. Guzman, J. N., Sánchez-Padilla, J., Chan, C. S. & Surmeier, D. J. Robust pacemaking in substantia nigra dopaminergic neurons. J. Neurosci. 29, 11011-11019 (2009).
165. Chan, C. S., Gertler, T. S. & Surmeier, D. J. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinsons disease. Mov. Disord. 25 (Suppl. 1), 63-70 (2010).
166. Guzman, J. N. et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ 1. Nature 468, 696-700 (2010).
167. Hurley, M. J., Brandon, B., Gentleman, S. M. & Dexter, D. T. Parkinsons disease is associated with altered expression of Cav1 channels and calcium-binding proteins. Brain 136, 2077-2097 (2013).
168. Dragicevic, E. et al. Cav1. 3 channels control D2 autoreceptor responses via NCS 1 in substantia nigra dopamine neurons. Brain 137, 2287-2302 (2014).
169. Anzalone, A. et al. Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors. J. Neurosci. 32, 9023-9034 (2012).
170. Parkinson Study Group. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinsons disease (STEADY PD). Mov. Disord. 28, 1823-1831 (2013).
171. Striessnig, J., Pinggera, A., Kaur, G., Bock, G. & Tuluc, P. L type Ca2+ channels in heart and brain. Wiley Interdiscip. Rev. Membr. Transp. Signal 3, 15-38 (2014).
172. Kang, S. et al. CaV1. 3 selective L type calcium channel antagonists as potential new therapeutics for Parkinsons disease. Nat. Commun. 3, 1146 (2012).
173. Huang, H. et al. Modest CaV1. 342 selective inhibition by compound 8 is β-subunit dependent. Nat. Commun. 5, 4481 (2014).
174. Ortner, N. J. et al. Pyrimidine 2, 4, 6 triones are a new class of voltage-gated L type Ca2+ channel activators. Nat. Commun. 5, 3897 (2014).
175. Tai, C. H., Yang, Y. C., Pan, M. K., Huang, C. S. & Kuo, C. C. Modulation of subthalamic T type Ca2+ channels remedies locomotor deficits in a rat model of Parkinson disease. J. Clin. Invest. 121, 3289-3305 (2011).
176. Scott, C. K., Dennis, M. L., Laudet, A., Funk, R. R. & Simeone, R. S. Surviving drug addiction: the effect of treatment and abstinence on mortality. Am. J. Publ. Health 101, 737-744 (2011).
177. Buttner, A. Review: the neuropathology of drug abuse. Neuropathol. Appl. Neurobiol. 37, 118-134 (2011).
178. Fowler, J. S., Volkow, N. D., Kassed, C. A. & Chang, L. Imaging the addicted human brain. Sci. Pract. Perspect. 3, 4-16 (2007).
179. Nestler, E. J. The neurobiology of cocaine addiction. Sci. Pract. Perspect. 3, 4-10 (2005).
180. Kosten, T. R. & George, T. P. The neurobiology of opioid dependence: implications for treatment. Sci. Pract. Perspect. 1, 13-20 (2002).
181. Pierce, R. C. & Kumaresan, V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci. Biobehav Rev. 30, 215-238 (2006).
182. Chen, B. T., Hopf, F. W. & Bonci, A. Synaptic plasticity in the mesolimbic system: therapeutic implications for substance abuse. Ann. NY Acad. Sci. 1187, 129-139 (2010).
183. Adinoff, B. Neurobiologic processes in drug reward and addiction. Harv. Rev. Psychiatry 12, 305-320 (2004).
184. Koob, G. F. & Volkow, N. D. Neurocircuitry of addiction. Neuropsychopharmacology 35, 217-238 (2010).
185. Rosse, R. B. et al. Nimodipine pharmacotherapeutic adjuvant therapy for inpatient treatment of cocaine dependence. Clin. Neuropharmacol. 17, 348-358 (1994).
186. Reimer, A. R. & Martin-Iverson, M. T. Nimodipine and haloperidol attenuate behavioural sensitization to cocaine but only nimodipine blocks the establishment of conditioned locomotion induced by cocaine. Psychopharmacol. 113, 404-410 (1994).
187. Pierce, R. C., Quick, E. A., Reeder, D. C., Morgan, Z. R. & Kalivas, P. W. Calcium-mediated second messengers modulate the expression of behavioral sensitization to cocaine. J. Pharmacol. Exp. Ther. 286, 1171-1176 (1998).
188. De Beun, R., Schneider, R., Klein, A., Lohmann, A. & De Vry, J. Effects of nimodipine and other calcium channel antagonists in alcohol-preferring AA rats. Alcohol 13, 263-271 (1996).
189. Giordano, T. P., Satpute, S. S., Striessnig, J., Kosofsky, B. E. & Rajadhyaksha, A. M. Up regulation of dopamine D2L mRNA levels in the ventral tegmental area and dorsal striatum of amphetamine-sensitized C57BL/6 mice: role of Cav1. 3 L type Ca2+ channels. J. Neurochem. 99, 1197-1206 (2006).
190. Giordano, T. P. et al. Molecular switch from L type Cav1. 3 to Cav1. 2 Ca2+ channel signaling underlies long-term psychostimulant-induced behavioral and molecular plasticity. J. Neurosci. 30, 17051-17062 (2010).
191. Schierberl, K. et al. Cav1. 3 L type Ca 2+ channels mediate long-term adaptation in dopamine D2L mediated GluA1 trafficking in the dorsal striatum following cocaine exposure. Channels 6, 11-17 (2012).
192. Schierberl, K. et al. Cav1. 2 L type Ca 2+ channels mediate cocaine-induced GluA1 trafficking in the nucleus accumbens, a long-term adaptation dependent on ventral tegmental area Cav1. 3 channels. J. Neurosci. 31, 13562-13575 (2011).
193. Rajadhyaksha, A. et al. L type Ca2+ channels mediate adaptation of extracellular signal-regulated kinase 1/2 phosphorylation in the ventral tegmental area after chronic amphetamine treatment. J. Neurosci. 24, 7464-7476 (2004).
194. Liu, Y. et al. Cav1. 2 and Cav1. 3 L type calcium channels regulate dopaminergic firing activity in the mouse ventral tegmental area. J. Neurophysiol. 112, 1119-1130 (2014).
195. Shulman, A., Jagoda, J., Laycock, G. & Kelly, H. Calcium channel blocking drugs in the management of drug dependence, withdrawal and craving. A clinical pilot study with nifedipine and verapamil. Aust. Fam. Physician 27 (Suppl. 1), 19-24 (1998).
196. Jimenez-Lerma, J. M. et al. Nimodipine in opiate detoxification: a controlled trial. Addiction 97, 819-824 (2002).
197. Newton, P. M. et al. A blocker of N and T type voltage-gated calcium channels attenuates ethanol-induced intoxication, place preference, self-administration, and reinstatement. J. Neurosci. 28, 11712-11719 (2008).
198. Bhutada, P. et al. Cilnidipine, an L/N type calcium channel blocker prevents acquisition and expression of ethanol-induced locomotor sensitization in mice. Neurosci. Lett. 514, 91-95 (2012).
199. Ferreira, M. A. et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat. Genet. 40, 1056-1058 (2008).
200. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 381, 1371-1379 (2013).
201. Wang, F., McIntosh, A. M., He, Y., Gelernter, J. & Blumberg, H. P. The association of genetic variation in CACNA1C with structure and function of a frontotemporal system. Bipolar Disord. 13, 696-700 (2011).
202. Paulus, F. M. et al. Association of rs1006737 in CACNA1C with alterations in prefrontal activation and fronto-hippocampal connectivity. Hum. Brain Mapp. 35, 1190-1200 (2014).
203. Erk, S. et al. Replication of brain function effects of a genome-wide supported psychiatric risk variant in the CACNA1C gene and new multi-locus effects. Neuroimage 94, 147-154 (2014).
204. Ament, S. A. et al. Rare variants in neuronal excitability genes influence risk for bipolar disorder. Proc. Natl Acad. Sci. USA 112, 3576-3581 (2015).
205. Gershon, E. S. et al. A rare mutation of CACNA1C in a patient with bipolar disorder, and decreased gene expression associated with a bipolar-associated common SNP of CACNA1C in brain. Mol. Psychiatry 19, 890-894 (2014).
206. Yoshimizu, T. et al. Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons. Mol. Psychiatry 20, 284 (2015).
207. Ostacher, M. J. et al. Pilot investigation of isradipine in the treatment of bipolar depression motivated by genome-wide association. Bipolar Disord. 16, 199-203 (2014).
208. Splawski, I. et al. CaV1. 2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119, 19-31 (2004).
209. Splawski, I. et al. Severe arrhythmia disorder caused by cardiac L type calcium channel mutations. Proc. Natl Acad. Sci. USA 102, 8089-8096; discussion 8086-8088 (2005).
210. Tian, Y. et al. Alteration in basal and depolarization induced transcriptional network in iPSC derived neurons from Timothy syndrome. Genome Med. 6, 75 (2014).
211. Krey, J. F. et al. Timothy syndrome is associated with activity-dependent dendritic retraction in rodent and human neurons. Nat. Neurosci. 16, 201-209 (2013).
212. Pinggera, A. et al. CACNA1D de novo mutations in autism spectrum disorders activate Cav1. 3 L type calcium channels. Biol. Psychiatry 77, 816-822 (2015).
213. Breitenkamp, A. F. et al. Rare mutations of CACNB2 found in autism spectrum disease-affected families alter calcium channel function. PLoS ONE 9, e95579 (2014).
214. Lu, A. T., Dai, X., Martinez-Agosto, J. A. & Cantor, R. M. Support for calcium channel gene defects in autism spectrum disorders. Mol. Autism 3, 18 (2012).
215. Splawski, I. et al. CACNA1H mutations in autism spectrum disorders. J. Biol. Chem. 281, 22085-22091 (2006).
216. Duval, E. R., Javanbakht, A. & Liberzon, I. Neural circuits in anxiety and stress disorders: a focused review. Ther. Clin. Risk Manag 11, 115-126 (2015).
217. Fox, A. S., Oler, J. A., Tromp, D. P., Fudge, J. L. & Kalin, N. H. Extending the amygdala in theories of threat processing. Trends Neurosci. 38, 319-329 (2015).
218. Felix-Ortiz, A. C. et al. BLA to vHPC inputs modulate anxiety-related behaviors. Neuron 79, 658-664 (2013).
219. Ricord, M. Academy of Medicine: Paris. Prov. Med. Surg. J. 2, 96-97 (1841).
220. Nasca, C. et al. Exposure to predator odor and resulting anxiety enhances the expression of the α2δ subunit of voltage-sensitive calcium channels in the amygdala. J. Neurochem. 125, 649-656 (2013).
221. Strawn, J. R. & Geracioti, T. D. Jr. The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic. Neuropsychiatr. Dis. Treat. 3, 237-243 (2007).
222. Shinnick-Gallagher, P., McKernan, M. G., Xie, J. & Zinebi, F. L type voltage-gated calcium channels are involved in the in vivo and in vitro expression of fear conditioning. Ann. NY Acad. Sci. 985, 135-149 (2003).
223. Lee, A. S. et al. Forebrain elimination of cacna1c mediates anxiety-like behavior in mice. Mol. Psychiatry 17, 1054-1055 (2012).
224. Dao, D. T. et al. Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans. Biol. Psychiatry 68, 801-810 (2010).
225. Fulga, I. G. & Stroescu, V. Experimental research on the effect of calcium channel blockers nifedipine and verapamil on the anxiety in mice. Rom. J. Physiol. 34, 127-136 (1997).
226. Busquet, P. et al. CaV1. 3 L type Ca2+ channels modulate depression-like behaviour in mice independent of deaf phenotype. Int. J. Neuropsychopharmacol. 13, 499-513 (2010).
227. Saegusa, H. et al. Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N type Ca2+ channel. EMBO J. 20, 2349-2356 (2001).
228. Cassidy, J. S., Ferron, L., Kadurin, I., Pratt, W. S. & Dolphin, A. C. Functional exofacially tagged N type calcium channels elucidate the interaction with auxiliary α2δ 1 subunits. Proc. Natl Acad. Sci. USA 111, 8979-8984 (2014).
229. Murakami, M. et al. Modified behavioral characteristics following ablation of the voltage-dependent calcium channel β3 subunit. Brain Res. 1160, 102-112 (2007).
230. Lee, J. & Shin, H. S. T type calcium channels and thalamocortical rhythms in sleep: a perspective from studies of T type calcium channel knockout mice. CNS Neurol. Disord. Drug Targets 6, 63-69 (2007).
231. Amer, A. & Maher, T. J. Nasal administration of the calcium channel blocker diltiazem decreases food intake and attenuates weight gain in rats. Pharmacol. Biochem. Behav. 82, 379-387 (2005).
232. Bell, T. J., Thaler, C., Castiglioni, A. J., Helton, T. D. & Lipscombe, D. Cell-specific alternative splicing increases calcium channel current density in the pain pathway. Neuron 41, 127-138 (2004).
233. Altier, C. et al. Differential role of N type calcium channel splice isoforms in pain. J. Neurosci. 27, 6363-6373 (2007).
234. Chang, S. Y. et al. Age and gender-dependent alternative splicing of P/Q type calcium channel EF hand. Neuroscience 145, 1026-1036 (2007).
235. Michailidis, I. E. et al. Age-related homeostatic midchannel proteolysis of neuronal L type voltage-gated Ca2+ channels. Neuron 82, 1045-1057 (2014).
236. Schrauwen, I. et al. A mutation in CABP2, expressed in cochlear hair cells, causes autosomal-recessive hearing impairment. Am. J. Hum. Genet. 91, 636-645 (2012).
237. Yang, P. S. et al. Switching of Ca2+-dependent inactivation of Cav1. 3 channels by calcium binding proteins of auditory hair cells. J. Neurosci. 26, 10677-10689 (2006).
238. Kuryshev, Y. A., Brown, A. M., Duzic, E. & Kirsch, G. E. Evaluating state dependence and subtype selectivity of calcium channel modulators in automated electrophysiology assays. Assay Drug Dev. Technol. 12, 110-119 (2014).
239. Brittain, J. M. et al. Suppression of inflammatory and neuropathic pain by uncoupling CRMP 2 from the presynaptic Ca2+ channel complex. Nat. Med. 17, 822-829 (2011).
240. Garcia-Caballero, A. et al. The deubiquitinating enzyme USP5 modulates neuropathic and inflammatory pain by enhancing Cav3. 2 channel activity. Neuron 83, 1144-1158 (2014).
241. Gadotti, V. M. et al. Small organic molecule disruptors of Cav3. 2-USP5 interactions reverse inflammatory and neuropathic pain. Mol. Pain 11, 12 (2015).
242. Inagaki, A., Frank, C. A., Usachev, Y. M., Benveniste, M. & Lee, A. Pharmacological correction of gating defects in the voltage-gated Cav2. 1 Ca2+ channel due to a familial hemiplegic migraine mutation. Neuron 81, 91-102 (2014).
243. Fischer, T. Z. et al. A novel Nav1. 7 mutation producing carbamazepine-responsive erythromelalgia. Ann. Neurol. 65, 733-741 (2009).